MedPath

A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

Phase 2
Recruiting
Conditions
Osteomyelitis
Pressure Ulcer, Stage IV
Registration Number
NCT06283979
Lead Sponsor
Biocomposites Ltd
Brief Summary

The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.

Detailed Description

The trial is an open-label, multi-center, randomized (1:1), controlled phase 2 trial in patients diagnosed with stage IV pressure ulcers.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Individual patient success and findings at the 8 week follow-up visit8 week

An individual patient treatment will be considered a success if there is complete wound closure and healing at the surgical site at two consecutive visits 2 weeks apart.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

NYU Langone Hospital - Long Island Clinical Research Center

🇺🇸

Mineola, New York, United States

NYU Langone Hospital - Long Island Clinical Research Center
🇺🇸Mineola, New York, United States
Anita Farha
Contact
516-663-9582
anita.farhi@nyulangone.org
Monica Benitez
Contact
516 663 9582
monica.benitez@nyulangone.org
Scott Gorenstein, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.